Back to top

Image: Bigstock

Community Health Trades at a Deep Discount to Peers: Hold or Fold?

Read MoreHide Full Article

Key Takeaways

  • Community Health's P/S ratio of 0.03X is far below the industry average of 0.73X.
  • CYH is expanding through acquisitions while Medicaid payments add $40-$45 million to Q2 EBITDA.
  • Debt fell to $9.6 billion, but lower cash-flow guidance highlights ongoing financial pressures.

Community Health Systems, Inc. (CYH - Free Report) is seeing improving operating volumes, along with continued progress in cost control, clinical quality, and patient experience. Recent divestitures are streamlining its portfolio while generating proceeds to reduce debt.

Community Health currently has a market capitalization of approximately $423.03 million. Based on short-term price targets from seven analysts, CYH has a mean target price of $3.18, implying 6% upside from its last closing price of $3.00. The stock currently carries a Zacks Rank #3 (Hold).

Valuation of CYH

Its forward price-to-sales (P/S) ratio of 0.03X is significantly below the industry average of 0.73X, suggesting an attractive valuation relative to its peers. The stock has risen 7.2% over the past three months compared with the broader industry’s 23.5% growth during the same period.

Zacks Estimates for CYH

The Zacks Consensus Estimate for revenues is pegged at $11.43 billion for 2026. The consensus estimate for 2026 earnings is pinned at a loss of 86 cents per share, and the same for 2027 loss has narrowed to 70 cents. It has witnessed one upward earnings estimate revision over the past month against two downward revisions, for 2026.

CYH’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed in the other two, delivering an average surprise of 106.2%.

Community Health Systems, Inc. Price, Consensus and EPS Surprise

Community Health Systems, Inc. Price, Consensus and EPS Surprise

Community Health Systems, Inc. price-consensus-eps-surprise-chart | Community Health Systems, Inc. Quote

Growth Drivers

CYH is continuing to invest in its existing markets through targeted acquisitions. In the second quarter of 2026, it completed the majority-stake acquisitions of Surgical Institute of Alabama and South Anchorage Surgery Center. As per management, these acquisitions are strengthening CYH's positions in core markets and meeting expectations for operating and financial performance. Expanding within established markets could strengthen physician relationships, broaden service capabilities, and create opportunities for incremental revenue growth.

CYH is benefiting from higher reimbursement rates and newly approved Medicaid state-directed payment programs. The Florida and Indiana programs contributed approximately $40-$45 million to its second-quarter 2026 EBITDA, including $20-$25 million related to prior periods. These additional payments helped offset some of the pressure from unfavorable payer and service mix. Higher reimbursement rates and supplemental Medicaid payments can support revenue and EBITDA growth, providing an important earnings tailwind for CYH.

The company continues to focus on operating efficiency while reshaping its portfolio. Same-store operating expense per adjusted admission increased only 0.3% in the second quarter of 2026, while contract labor spending declined 5.6% and supplies expense fell 70 basis points to 14.2%. CYH also used approximately $600 million of divestiture proceeds to repurchase debt. Total operating expenses declined 6.8% year over year in the first half of 2026. Long-term debt amounted to approximately $9.6 billion, down from $10.4 billion as of year-end 2025. Continued cost discipline could support EBITDA stabilization, while debt reduction could reduce financial pressure and improve financial flexibility.

CYH: Key Risks

Community Health continues to face financial and operational pressures. Adjusted EBITDA declined to $330 million from $380 million a year ago, while unfavorable payer and service mix, higher uncompensated care and continued softness in elective procedures weighed on margins. Medical specialist fees also increased 19% year over year on a same-store basis, adding to cost pressures.

CYH also faces pressure on cash generation. It used $209 million of cash in operating activities in the first half of 2026 compared to $208 million cash generated from operating activities in the prior-year period. Although operating cash flow improved to $87 million in second-quarter 2026, the company lowered its 2026 operating cash flow guidance to $300-$500 million from $600-$700 million. Continued operating pressures and cash-flow volatility could limit financial flexibility and slow progress toward sustained free cash flow generation.

Top-Ranked Players

Some better-ranked stocks in the broader Medical space areTenet Healthcare Corporation (THC - Free Report) ), BrightSpring Health Services, Inc. (BTSG - Free Report) and Surgery Partners, Inc. (SGRY - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Tenet Healthcare’s 2026 earnings is pegged at $20.16 per share, indicating a 20.1% year-over-year improvement. THC beat earnings estimates in each of the trailing four quarters, with the average surprise being 22.7%. The consensus estimate for 2026 revenues is pinned at $22.17 billion, implying 4% year-over-year growth.

The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.78 per share, which has witnessed five upward revisions in the past 30 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for 2026 revenues is pinned at $15.24 billion, implying 18.1% year-over-year growth.

The Zacks Consensus Estimate for Surgery Partners’ 2026 earnings is pegged at 42 cents per share, which has witnessed two upward revisions in the past 30 days, with no movement in the opposite direction. SGRY beat earnings estimates in two of the trailing four quarters and missed in the other two, with the average surprise being 96.78%. The consensus estimate for 2026 revenues is pinned at $3.43 billion.

Published in